Genes are part of the DNA that provides the blueprint instructions to the cells for making proteins. A mutation or a defect in the gene can prevent the cells from creating an accurate expression of the protein or a diminished ability to do so. Gene therapy is the science of altering DNA to restore normal protein expression by the cells or even silence proteins that may cause debilitating diseases.
- Significant progress has been made in improving the understanding of using different delivery vehicles or vectors to safely deliver the therapeutic DNA altering payload. For example, CRISPR, which makes addition and deletion edits directly to the DNA strand, is a popular editing tool in gene therapy.
- The first gene therapy approved in Western Europe, UniQure's Glybera, turned out to be a flop. The company withdrew it from the market in 2017 and is shifting its focus to hemophilia treatments.
ETFs:
The Nasdaq Biotech (IBB) and the S&P Biotech (XBI) indexes
(by market cap)
Company name Mkt Cap▼
Company name Mkt Cap▼
- VRTX Vertex Pharmaceuticals 73.83B; Massachusetts
- ALNY Alnylam Pharmaceuticals 23.28B; Massachusetts
- BMRN BioMarin Pharmaceutical 15.90B; California
- SRPT Sarepta Therapeutics 9.79B Massachusetts
- IONS Ionis Pharmaceuticals 6.18B; California
- CRSP CRISPR Therapeutics AG 4.09B; Switzerland
- NTLA Intellia Therapeutics 3.96B; Massachusetts
- BEAM Beam Therapeutics 3.26B; Massachusetts
- PTCT PTC Therapeutics 3.19B; New Jersey
- RARE Ultragenyx Pharmaceutical 2.76B; California
- VERV Verve Therapeutics 2.16B; Massachusetts
- RGNX REGENXBIO 981.75M; Maryland
- QURE uniQure N.V. 846.73M; Netherlands
- EDIT Editas Medicine 823.47M; Massachusetts
- SGMO Sangamo Therapeutics 673.18M; California
- BLUE bluebird bio 463.50M; Massachusetts
- MGTX MeiraGTx 338.48M; New York
- SELB Selecta Biosciences 248.92M; Massachusetts
- VYGR Voyager Therapeutics 198.26M; Massachusetts
- ADVM Adverum Biotechnologies 91.35M; California
- FIXX Homology Medicines 85.53M; Massachusetts
- SLDB Solid Biosciences 51.29M; Massachusetts
- AVRO AVROBIO 29.40M; Massachusetts
- AGTC Applied Genetic Technologies 27.66M; Florida
- ABEO Abeona Therapeutics 25.76M; New York
- SIOX Sio Gene Therapies 22.04M; New York; formerly known as Axovant Gene Therapies (NASDAQ: AXGT)
Acquisitions
- Alexion Pharma (ALXN) acquired by AstraZeneca (AZN) for $175 per share. (Dec 2020)
- Prevail Therapeutics (PRVL) acquired by Lilly (LLY) for $22.50 per share or ~$880 mln. (Dec 2020)
- Audentes Therapeutics (BOLD) acquired by Astellas (ALPMY) for $60/share. (December 3, 2019)
- Nightstar Therapeutics (NITE) acquired by Biogen (BIIB) for $800 mln. (March 2019)
- Spark Therapeutics (ONCE) acquired by Roche (RHHBY) for $4.8 bln. (February 2019)
- Celgene (CELG) acquired by Bristol-Myers Squibb (BMY) for $102.43/share or approx. $74 billion. (January 2019)
- TESARO (TSRO) acquired by GlaxoSmithKline (GSK) for $5.1B. (January 2019)
- AveXis (AVXS) acquired by Novartis (NVS) for $8.7 bln. (April 9, 2018)
- Wilson Therapeutics acquired by Alexion Pharma (ALXN) for $855 Million. (April 2018)
- Kite Pharma (KITE) acquired by Gilead Sciences (GILD) for approximately $11.9 billion (October 2017)
No comments:
Post a Comment